Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352779 · ClinicalTrials.gov registry record · NA
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
A NA study, sponsored by Gary Morrow.
- Completed
- Registry status
- NA
- Development phase
- 108
- Enrollment target
NCT02352779: Completed NA study, sponsored by Gary Morrow.
NCT02352779 is a NA study that has completed, run by Gary Morrow. The registered enrollment target is 108 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02352779, a NA study, has completed, sponsored by Gary Morrow.
- COMPLETED
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies omega-3 fatty acid in reducing cancer-related fatigue in breast cancer survivors. Supplementation with omega-3 fatty acid may help reduce cancer-related fatigue in breast cancer survivors.
Primary Outcome
BFI-SF is a 4 item questionnaire to assess the severity of fatigue, ranging from 0 (No Fatigue) to 10 (As bad as you can imagine). MFSI-SF is a 30 item questionnaire to assess the level of fatigue in terms of general fatigue, physical fatigue, emotional fatigue, mental fatigue, and vigor). First four subscales (general, physical, emotional, and mental) are summed and the vigor scale is subtracted to create fatigue total score with a range of -32 (low fatigue) to 96 (high fatigue).
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DIETARY_SUPPLEMENT Omega-3 Fatty Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-04 |
| Phase | NA |
What the finished NCT02352779 record still lists
NCT02352779 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02352779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02352779 about?
NCT02352779 is a clinical study titled "Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors". This randomized pilot clinical trial studies omega-3 fatty acid in reducing cancer-related fatigue in breast cancer survivors. Supplementation with omega-3 fatty acid may help reduce cancer-related fatigue in breast cancer survivors.
What is the current status of trial NCT02352779?
This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2015-02. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02352779?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Omega-3 Fatty Acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02352779?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02352779's enrollment target sits among peer trials
108 825th of 2000 higher than 1,171 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia